Cerebrolysin is a pig-brain-derived mixture intended to help damaged brain cells survive and maintain the connections used for movement, speech and memory.
What Cerebrolysin does and why that matters
Cerebrolysin is a mixture of small peptides and amino acids made from pig brain tissue. It is intended to act like signals that help brain cells survive damage and maintain connections. The practical hope is that a person recovering from a stroke or other brain injury might preserve more movement, speech, memory or independence. Its active ingredients are not clearly defined, and a 2023 Cochrane stroke review did not find a reliable improvement in day-to-day function. [1,2]
Function evidence: Proposed brain-cell support; day-to-day benefit not shown
What recovery would mean in real life
After a stroke, a meaningful benefit is not simply a change in a laboratory marker. It would mean regaining more movement, speaking or understanding more easily, remembering daily tasks, or needing less help with washing, dressing and eating. The 2023 Cochrane review did not establish those improvements and found no reduction in death. It also reported a possible increase in nonfatal serious adverse events. That leaves the hoped-for recovery benefit unconfirmed and makes the safety uncertainty important, not secondary. [1,2]
What supports this description: Systematic review of randomized stroke trials; functional benefit not established
Cerebrolysin Dosing status
Dose: No consumer dose is established or recommended here. | Frequency: No routine treatment schedule established. | Cycle: No validated consumer cycle. | Route: No routine patient route established.
Preparation: No patient reconstitution recipe. Trial preparation is not a recommendation..
Cerebrolysin is a mixture of peptides derived from pig brain. It is used in some countries but is not FDA-approved in the United States. A 2023 Cochrane review of acute ischemic stroke found no reduction in deaths and no usable evidence of better function. It also found a possible increase in nonfatal serious adverse events. [1,2]
Cerebrolysin Effects
Acute ischemic stroke. The 2023 Cochrane review found no evidence of reduced all-cause death and could not confirm functional benefit because usable functional-outcome data were not reported. [1]
Cerebrolysin Side Effects
Nonfatal serious adverse events. The review found a possible increase in nonfatal serious adverse events (risk ratio 2.39, 95% CI 1.10–5.23). The certainty and trial limitations matter; this is a signal, not proof that every event was caused by Cerebrolysin. [1]
Product and jurisdiction differences. Use in another country is not FDA approval, and results for a specified IV trial product do not validate unregulated products or other routes. [1,2]
Frequently Asked Questions About Cerebrolysin
Does Cerebrolysin improve recovery after stroke?
The 2023 Cochrane review did not establish a mortality or functional-outcome benefit in acute ischemic stroke. [1]
Is Cerebrolysin FDA-approved?
No. It is not an FDA-approved drug in the United States. [2]
Evidence
Clinical trials; uncertain benefit and a possible serious-adverse-event signal. Cerebrolysin is a mixture of peptides derived from pig brain. It is used in some countries but is not FDA-approved in the United States. A 2023 Cochrane review of acute ischemic stroke found no reduction in deaths and no usable evidence of better function. It also found a possible increase in nonfatal serious adverse events. [1,2]
Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev, 2023. PMID 37818733
U.S. Food and Drug Administration Unapproved Drugs , . Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
